Inhibikase Therapeutics to Present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit

BOSTON and ATLANTA , Feb. 15, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that Milton Werner, Ph.D., President and Chief Executive Officer of Inhibikase, will present at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit. The event is being held in San Francisco, California between February 21-23, 2023.

Presentation Details:

Presentation Title: A Small Molecule c-Abl Kinase Inhibitor, IkT-148009, as a Potential Disease Modifying Therapy in Parkinson's Disease
Track: Translational & Clinical: Reviewing the Clinical Developments in Parkinson's Disease Research Date & Time: Thursday, February 23, 2023, 10:45am PT
Location: Hyatt Centric Fisherman's Wharf San Francisco

The presentation will detail the pathology of Parkinson's Disease as well as the potential role of c-Abl as a target for a disease modifying therapy. Dr. Werner will highlight therapeutic evaluation of efficacy for IkT-148009 in animal models of inherited and idiopathic Parkinson's Disease and results from Inhibikase's Phase 1 '101' trial. The presentation will further detail the Company's development strategy for its ongoing Phase 2a '201' trial for IkT-148009.

About Inhibikase (

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.

Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use TwitterFacebookLinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements, including that results in animal studies may not be replicated in humans. Important factors that could cause actual results to differ materially from those in the forward-looking statements include factors that are delineated in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.


Company Contact:
Milton H. Werner, Ph.D.
President & CEO

Investor Relations:
Alex Lobo
SternIR, Inc.

Cision View original content to download multimedia:

SOURCE Inhibikase Therapeutics, Inc.